SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-029594
Filing Date
2023-08-21
Accepted
2023-08-21 15:32:22
Documents
58
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 2413995
2 ex31-1.htm EX-31.1 19160
3 ex31-2.htm EX-31.2 19518
4 ex32-1.htm EX-32.1 8318
5 ex32-2.htm EX-32.2 7956
  Complete submission text file 0001493152-23-029594.txt   11617279

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE atrx-20230630.xsd EX-101.SCH 52533
7 XBRL CALCULATION FILE atrx-20230630_cal.xml EX-101.CAL 37407
8 XBRL DEFINITION FILE atrx-20230630_def.xml EX-101.DEF 246915
9 XBRL LABEL FILE atrx-20230630_lab.xml EX-101.LAB 403344
10 XBRL PRESENTATION FILE atrx-20230630_pre.xml EX-101.PRE 318546
52 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 2065185
Mailing Address P.O. BOX 2161 WAKE FOREST NC 27588
Business Address P.O. BOX 2161 WAKE FOREST NC 27588 919-578-5901
Adhera Therapeutics, Inc. (Filer) CIK: 0000737207 (see all company filings)

IRS No.: 112658569 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-13789 | Film No.: 231189000
SIC: 2834 Pharmaceutical Preparations